SENS - Senseonics Holdings, Inc.
NYSE
->
Healthcare
->
Diagnostics & Research
Germantown,
United States
Type: Equity
SENS price evolution
SENS
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.76 | |||
| Short term investments | ||||
| Net receivables | $6.6 | $5.46 | ||
| Inventory | $8.78 | $9.73 | ||
| Total current assets | $130.03 | $146.14 | ||
| Long term investments | ||||
| Property, plant & equipment | $6.36 | $6.2 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $138.22 | $154.06 | ||
| Current liabilities | ||||
| Accounts payable | $4.57 | $2.67 | ||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $17.26 | $17.3 | ||
| Long term debt | $41.2 | $40.48 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $64.77 | $64.34 | ||
| Shareholders' equity | ||||
| Retained earnings | -$869.26 | -$852.07 | ||
| Other shareholder equity | -$0.01 | -$0.06 | ||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.76 | $1.14 | $4.26 | $18.2 |
| Short term investments | ||||
| Net receivables | $6.6 | $2.79 | $2.42 | $2.99 |
| Inventory | $8.78 | $7.31 | $6.32 | $5.28 |
| Total current assets | $130.03 | $161.2 | $144.41 | $30.25 |
| Long term investments | ||||
| Property, plant & equipment | $6.36 | $4.14 | $1.31 | $1.56 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.67 | |||
| Total investments | ||||
| Total assets | $138.22 | $177.67 | $198.93 | $35.92 |
| Current liabilities | ||||
| Accounts payable | $4.57 | $0.42 | $1.2 | $1.76 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $17.26 | $31.47 | $18.39 | $16.64 |
| Long term debt | $41.2 | $56.38 | $59.8 | $57.22 |
| Total noncurrent liabilities | $160.55 | |||
| Total debt | ||||
| Total liabilities | $64.77 | $142.59 | $384.46 | $177.19 |
| Shareholders' equity | ||||
| Retained earnings | -$869.26 | -$808.87 | -$950.99 | -$648.51 |
| Other shareholder equity | -$0.01 | -$0.68 | -$0.21 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.62 | $3.71 | ||
| Cost of revenue | ||||
| Gross Profit | $0.76 | $0.82 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $18.33 | $17.86 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$41.8 | $120.5 | ||
| Net income | ||||
| Net income | -$60.39 | $104.23 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.95 | $21.3 | $18.91 | |
| Cost of revenue | ||||
| Gross Profit | -$17.37 | -$19.45 | -$8.15 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $62.08 | $111.96 | $79.49 | |
| Operating income | -$79.13 | -$130.66 | -$87.58 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $16.17 | $11.8 | $8.28 | |
| Net income | ||||
| Net income | -$175.17 | -$115.55 | -$93.97 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $19.53 | $42.11 | $19.67 | -$148.75 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $31.42 | $4.2 | $6.04 | $220.08 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $2.02 | $11.96 | $5.55 | $15.25 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Net income | -$175.17 | -$115.55 | -$93.97 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$67.42 | -$136.05 | -$90.77 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$148.75 | -$0.18 | -$1.04 | $19.43 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $220.08 | -$10.13 | $96.24 | $191.99 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $15.25 | -$77.73 | -$40.85 | $120.64 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 30.86% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |